[{"NetIncomeLoss_1_Q1_USD":-239754.0,"TemporaryEquityCarryingAmountAttributableToParent_0_Q1_USD":157122450.0,"SaleOfStockConsiderationReceivedPerTransaction_1_Q1_USD":30000.0,"AssetsCurrent_0_Q1_USD":1451284.0,"AccruedIncomeTaxes_0_Q1_USD":7389.0,"AccruedLiabilitiesCurrent_0_Q1_USD":202089.0,"InterestIncomeOther_1_Q1_USD":26666.0,"CommitmentsAndContingencies_0_Q1_USD":null,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":16675000.0,"GeneralAndAdministrativeExpense_1_Q1_USD":211731.0,"PreferredStockSharesOutstanding_0_Q1_shares":null,"Liabilities_0_Q1_USD":6138214.0,"Cash_0_Q1_USD":1300000.0,"AdditionalPaidInCapitalCommonStock_0_Q1_USD":5362242.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":1258456.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":68322.0,"FranchisorCosts_1_Q1_USD":24114.0,"AssetsHeldInTrustNoncurrent_0_Q1_USD":166809388.0,"StockIssuedDuringPeriodSharesIssuedForServices_1_Q1_shares":25.0,"CashAndCashEquivalentsPeriodIncreaseDecrease_1_Q1_USD":-55629.0,"CommonStockValue_0_Q1_USD":566.0,"IncomeTaxExpenseBenefit_1_Q1_USD":525.0,"IncreaseDecreaseInAccruedLiabilities_1_Q1_USD":127162.0,"RestrictedInvestmentsPercentOfNetAssets_0_Q1_pure":0.2,"SaleOfStockPricePerShare_0_Q1_USD":10.0,"CommonStockSharesIssued_0_Q1_shares":5665005.0,"Assets_0_Q1_USD":168260672.0,"StockRedeemedOrCalledDuringPeriodValue_1_Q1_USD":-239760.0,"PreferredStockSharesIssued_0_Q1_shares":null,"RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_1_Q1_USD":30000.0,"AccountsPayableCurrent_0_Q1_USD":68322.0,"LiabilitiesCurrent_0_Q1_USD":301964.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-55629.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-239229.0,"CommonStockSharesOutstanding_0_Q1_shares":5665005.0,"DebtInstrumentConvertibleConversionPrice1_0_Q1_USD":10.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-362800.0,"StockholdersEquity_0_Q1_USD":5000008.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":0.0,"PrepaidExpenseCurrent_0_Q1_USD":192828.0,"CashFDICInsuredAmount_0_Q1_USD":250000.0,"BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_0_Q1_pure":1.0,"PreferredStockSharesAuthorized_0_Q1_shares":1000000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":168260672.0,"PreferredStockValue_0_Q1_USD":null,"BusinessCombinationConsiderationTransferred1_1_Q1_USD":1500000.0,"InvestmentIncomeInterest_1_Q1_USD":26666.0,"OperatingIncomeLoss_1_Q1_USD":-265895.0,"CommonStockSharesAuthorized_0_Q1_shares":30000000.0,"IncreaseDecreaseInAccruedTaxesPayable_1_Q1_USD":525.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.0001,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.0001,"SharePrice_0_Q1_USD":0.35,"IncreaseDecreaseInPrepaidExpense_1_Q1_USD":9332.0,"Ticker":"TNGX","CIK":"1819133","name":"BCTG ACQUISITION CORP.","OfficialName":"Tango Therapeutics Inc.","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"650767383.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210514"}]